Author: Customer Service

MONTREAL, Jan. 09, 2026 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (TSXV CDPR) (OTCQB GPPRF) (FRA N8HP) (the Company or CDPR) is pleased to provide an operational review and corporate update highlighting key workstreams completed and consolidated at the Quiulacocha Tailings Project, as the Company transitions toward the next stage of project execution. This update builds on the technical and permitting progress outlined in the Company’s December 10, 2025 news release and reflects the completion and integration of several core Phase 1 programs. Project Positioning Update Over the course of 2025, the Company completed and consolidated the principal technical, environmental and regulatory workstreams required to materially advance the readiness of the Quiulacocha Project. Collectively, this work has reduced execution risk within...

PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company has submitted a protocol amendment to the U.S. Food & Drug Administration (“FDA”) for its Phase 3 VERSATILE-003 clinical trial. The proposed amendment to the VERSATILE-003 Phase 3 trial changes the PFS endpoint to a primary endpoint that can be evaluated earlier with significant statistical power, potentially providing the basis for accelerated approval of PDS0101. Median overall survival (mOS) remains...

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE WOODLANDS, TX, Jan. 09, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium demonstrating rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages. The analysis expands upon previously reported data from the Company’s ongoing clinical evaluation and examines outcomes by pancreatic cancer stage in patients treated for severe pancreatic cancer-related...

Kvika banki hf.’s („Kvika“or „the Company“) Nomination Committee (“the Committee”) invites those interested to submit their nominations or candidacies to the Board of Directors of the Company to the Committee. The Committee prepares and presents proposals for candidates for election to the Company’s Board of Directors at its Annual General Meeting (AGM) and at shareholder meetings where board elections are on the agenda. The Committee’s proposals shall aim to ensure that the Board of Directors is composed at any given time of diverse range of knowledge and experience that is useful to the Company in policymaking and monitoring in the environment in which the company operates at any given time. The Nomination Committee has an advisory role in the selection of directors of Kvika and shall submit its proposals to a shareholders’...

LAS VEGAS, Jan. 09, 2026 (GLOBE NEWSWIRE) — AMC Robotics Corporation (Nasdaq: AMCI) (“AMC Robotics” or the “Company”), a leading AI-driven robotics solutions company, today announced its participation at CES® 2026. The Company demonstrated its latest artificial intelligence–powered technologies, headlined by Kyro™, its proprietary quadruped robotic platform. The demonstration comes at a pivotal time for the industry. During his CES 2026 keynote, NVIDIA CEO Jensen Huang declared that “the ChatGPT moment for physical AI is here,” describing a new era where machines move beyond digital processing to “understand, reason, and act in the real world.” At CES, AMC Robotics showcased how Kyro™ utilizes these breakthroughs through advanced mobility, autonomous navigation, and AI-enabled perception. By integrating these “thinking”...

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in March 2026; pending positive results, an NDA submission is planned for the second half of 2026 Accelerating U.S. launch readiness for QTORIN™ rapamycin for microcystic LMs which has the potential to become the first FDA-approved therapy and a first-line, standard-of-care treatment for this serious, lifelong disease affecting an estimated more than 30,000 diagnosed patients in the U.S. Following positive Phase 2 results for QTORIN™ rapamycin for the treatment of cutaneous venous malformations announced in December 2025, requested a Preliminary Breakthrough Therapy Designation Advice meeting with the U.S. Food and...

Seasoned Capital Markets and Financial Executive to Drive Strategic Growth and Market Expansion BELVIDERE, NJ, Jan. 09, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce, today announced that Matthew McConnell, a member of the Company’s Board of Directors, has joined Edible Garden’s senior leadership team full time as Executive Vice President Strategic Partnerships, effective immediately. In this role, Mr. McConnell will be responsible for advancing the Company’s strategic initiatives, strengthening relationships with investors and partners, and supporting long-term growth objectives across key channels. Mathew has worked on Wall Street for over 40...